Clinical studies have indicated that SSRI and SNRI antidepressant use during pregnancy has the potential to influence fetal development, which can result in congenital birth defects in newborns. Celexa, Effexor, Lexapro, Paxil, Prozac, Wellbutrin, and Zoloft are classified as SSRI and SNRI antidepressants. Major congenital birth defects include, but are not limited to:
In 2011, the FDA announced that women who used Yaz, Yasmin, or Ocella were 74% more likely to experience a blood clot compared to women who were using other birth control pills. Lawsuit filings allege that Bayer failed to warn women of the risks associated with taking their contraceptive. These risks include, but are not limited to:
Pradaxa is an anticoagulant, or blood thinner, that is typically used to reduce the risk of strokes or serious blood clots in people who have non-valvular atrial fibrillation. Clinical studies have indicated that Pradaxa can drastically increase the risk for extracranial, gastrointestinal tract, and internal bleeding, which often prove to be fatal. Myocardial Infarction and Stroke risks are also increased.
Transvaginal Mesh is a type of surgical mesh that is used to treat pelvic organ prolapse (POP), urinary incontinence and similar problems. The FDA has issued several public health notifications stating serious complications associated with these surgical implant devices that may require additional, corrective surgeries. Complications include, but are not limited to:
Topamax is an anti-epileptic, or anti-seizure, medication that became one of the most widely prescribed drugs for migraine headaches which affects almost 30 million Americans. In 2011, the FDA escalated Topamax to a Pregnancy Category D, which means there is positive evidence of fetal risk if taken during pregnancy. Congenital birth defects include, but are not limited to:
Actos is an anti-diabetic medication used to treat Type II Diabetes in patients. Actos is used in combination with insulin or other medications, and is not used to treat Type I Diabetes. In 2011, the FDA issued a statement to the public warning of the increased bladder cancer risk associated with Actos use.